Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

NOVEMBER 18, 2020

These results will be presented by the lead investigators of OBI Pharma’s novel anti-Globo H therapeutic cancer vaccine, OBI-833. ” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

Alta Sciences

SEPTEMBER 27, 2024

This issue also covers classes of immunomodulators, including monoclonal antibodies, CAR-T cells, and vaccines; immunotherapy trials, focusing on complex study designs and diverse patient populations; and bioanalytical methods and assays, including pharmacokinetics and anti-drug antibodies (ADA).

Clinical Trials 52

Clinical Trials Trials Pharmacokinetics Small Molecule 52

The Pharma Data

SEPTEMBER 9, 2020

The BNT162b2 vaccination also cleared the nose of detectable viral RNA in 100% of the SARS-CoV-2 challenged rhesus macaques within 3 days after the infection. Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc. Jansen, Ph.D.,

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

thought leadership

SEPTEMBER 29, 2023

Government begins its fiscal year on October 1, it signifies the annual revisions in FDA User Fees, which have an impact on applications and facilities associated with Prescription Drugs (including small molecules, vaccines, cell and gene therapy products, biologics, etc.), Generic Drugs, Biosimilars, and Medical Devices.

FDA 45

FDA Small Molecule Biosimilars Government 45

The Pharma Data

AUGUST 20, 2020

times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation. Jansen, Ph.D.,

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

Drug Target Review

DECEMBER 21, 2023

mRNA biology has become widely recognised as a new “drug mine” RNAi drugs are in the market and mRNA vaccines, initially developed for Covid-19, are already in trials for cancer. All of these are novel targets to be explored in small molecule drug discovery as well as for improving the efficacy of mRNA vaccines.

Disease 105

Disease Small Molecule Vaccine Drugs 105

The Pharma Data

FEBRUARY 18, 2022

BioNTech SE (Nasdaq: BNTX, “BioNTech”) has taken a next step to improve vaccine supply in Africa. The company has introduced its approach to establishing scalable vaccine production by developing and delivering turnkey mRNA manufacturing facilities based on a container solution.

Vaccine 40

Vaccine Production Small Molecule Therapies 40

PerkinElmer

JANUARY 21, 2021

AlphaLISA assay technology can be used in small molecule discovery but can also be applied to large molecule discovery, including biologics, vaccines and cell-based therapies. The next focus for the team is to identify similar small molecules to the 25 hits they uncovered and then try to improve the potency of each.

Treatment 52

Treatment Small Molecule Drugs Virus 52

Drug Target Review

JULY 18, 2024

Our recent Nature Medicine publication is a good example of where liquid biopsy data was used alongside T cell responses to make decisions during a dose escalation of a new cancer vaccine candidate, ELI-002 2P 1. How did Elicio use ctDNA detection in the AMPLIFY-201 study of the therapeutic cancer vaccine candidate ELI-002?

Drug Development 59

Drug Development Clinical Trials Drugs Vaccine 59

The Pharma Data

OCTOBER 14, 2020

Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics. Such aptamers have the potential to identify biomarkers for protective CoV-2 immunity and may lead to accelerated precision medicine-driven vaccines designed to protect against COVID-19. CHATHAM, N.J., About TNX-1800. 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. .

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

The Pharma Data

MAY 6, 2022

Food and Drug Administration (FDA) to expand the approval of COMIRNATY® (COVID-19 Vaccine, mRNA) to include individuals ages 12 through 15 years. In the trial, a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) was 100% effective (95% confidence interval [CI, 87.5,

FDA Approval 52

FDA Approval Licensing Licensing FDA 52

The Pharma Data

AUGUST 5, 2021

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Therapies 52

Therapies Small Molecule Vaccine Science 52

The Pharma Data

JANUARY 17, 2021

Johnson & Johnson published interim Phase I/IIa data in the New England Journal of Medicine showing its single-dose COVID-19 vaccine candidate created an immune response that lasted at least 71 days. The data showed that the vaccine induced an immune response and was generally well-tolerated. Most Read Today. Source link.

Immune Response 52

Immune Response Small Molecule Clinical Trials Trials 52

The Pharma Data

NOVEMBER 9, 2020

Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.

Vaccine 40

Vaccine Clinical Trials Trials FDA 40

The Pharma Data

NOVEMBER 23, 2020

Over the years, Ultimovacs’ lead therapeutic cancer vaccine program, UV1, has garnered interest from key opinion leaders, physicians and pharmaceutical companies based on its encouraging potential in a range of solid tumor cancers,” stated Ton Berkien, Chief Business Officer at Ultimovacs. View source version on businesswire.com: [link].

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

Vial

DECEMBER 11, 2023

The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs. Genetic diversity of HCV is also a significant challenge in HGC vaccine development. In light of these issues, researchers determine that developing an HCV vaccine would be an important contribution to eliminating HCV.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

The Pharma Data

OCTOBER 25, 2020

Army Medical Research and Development (USAMRDC ) initiated a Phase I clinical trial of its novel vaccine against COVID-19. The vaccine candidate is called “spike ferritin nanoparticle” (SpFN) and uses ferritin—“attaching a certain type of spike protein to a polymerized version of ferritin,” according to the organization.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

JANUARY 13, 2021

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JULY 15, 2021

The company’s proprietary chemical biology-based platform enables the development of therapeutic peptides and proteins with tunable activity that can be controlled using small molecules. www.protomer.com.

Small Molecule 52

Small Molecule Engineering Therapies Science 52

The Pharma Data

APRIL 28, 2021

I am honored that Takeda receives two awards for the production and packaging of small molecule solid dosage form products,” said Thomas Wozniewski, global manufacturing & supply officer of Takeda. “In We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

Packaging 52

Packaging Small Molecule Pharmaceutical Companies Engineering 52

Codon

DECEMBER 12, 2024

Similarly, about 40 percent of people with a deficiency in either IRAK-4 or MyD88 — key signaling molecules just downstream of the pattern recognition receptors — die before reaching adulthood, despite receiving vaccines, antibiotics, and advanced medical treatment. Creating Countermeasures Vaccine development can be fast.

DNA 104

DNA RNA Vaccine Virus 104

The Pharma Data

DECEMBER 9, 2020

With the expected Emergency Use Authorization (EUA) of Pfizer – BioNTech and Moderna ’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience? Tranquis Therapeutics.

Marketing 52

Marketing Small Molecule Disease Pharmaceuticals 52

NIH Director's Blog: Drug Development

MAY 21, 2020

One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules. In the U.S. Stay tuned for more information about these potentially significant advances in the next few months. 2020 May 18.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

DECEMBER 20, 2020

CureVac announced it has enrolled the first volunteer in the pivotal Phase IIb/III trial of its own mRNA vaccine candidate, CVnCoV against COVID-19. The technology used for the CureVac vaccine is similar to that utilized by Pfizer-BioNTech and Moderna. Russia’s Sputnik V COVID-19 vaccine demonstrated 91.4% Here’s a look.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

The Pharma Data

MARCH 28, 2022

A broad Phase 1 clinical program of small molecules and biologics. These candidate medicines include oral small molecules, degraders, synthetic cytokines, and several NANOBODY molecules, designed to simultaneously tackle two proven targets, thus aiming to break efficacy ceilings.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

The Pharma Data

JANUARY 10, 2021

When our backs were against the wall, the biotech/biopharma community came together to create not one, but two vaccines currently approved for emergency use in the U.S. There is a goldmine, called mRNA, that some diggers have been digging for 30 years, finding a very small part of it,” said Yochi Slonim ?,

Vaccine 52

Vaccine Disease Regulations Small Molecule 52

The Pharma Data

MARCH 13, 2022

With a focus on immuno-inflammatory conditions in Rheumatology, Gastroenterology and Medical Dermatology, our current portfolio of approved medicines and investigational molecules spans multiple action and delivery mechanisms, from topicals to small molecules, biologics and biosimilars.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Biosimilars Disease 52

The Pharma Data

JANUARY 6, 2021

. “We are leveraging our strengths in process development and manufacturing for a wide range of biopharmaceuticals such as antibodies, recombinant proteins, gene therapies and vaccines,” said Martin Meeson , chief executive officer at FUJIFILM Diosynth Biotechnologies. Overview of New Site. 1.

Packaging 52

Packaging Small Molecule Production FDA Approval 52

The Pharma Data

DECEMBER 2, 2020

The drug is a small-molecule inhibitor of the S. TSK Laboratory – Netherlands-based TSK developed a new needle that could save 4% to 8% of vaccine doses, which could prevent wasted parts of the COVID-19 preventative medicines. Horizon Discovery Group – U.K.-based for its cGMP-compliant CHOSOURCE platform.

Licensing 52

Licensing Licensing DNA Vaccine 52

The Pharma Data

JANUARY 11, 2021

is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. MediciNova, Inc.

Clinical Trials 52

Clinical Trials Trials Small Molecule Vaccine 52

DrugBank

AUGUST 15, 2024

This first-in-class reversible small molecule inhibitor targets specific mutations in the EGFR and HER2 genes, which are known to drive tumor growth in several types of cancer.

Drug Development 80

Drug Development Clinical Trials Drugs Therapies 80

The Pharma Data

AUGUST 18, 2020

Small molecule discovery. The drug repositioning pillar builds on Johnson & Johnson’s ongoing partnership with the prestigious Rega Institute at KU Leuven in Belgium, where a team of scientists are screening molecule libraries containing thousands of existing compounds to determine if they have potential as COVID-19 treatments.

Treatment 52

Treatment Pharmaceutical Companies Research Small Molecule 52

Drug Target Review

DECEMBER 13, 2024

Typically, these combinations include an immune checkpoint inhibitor (CPI; eg, anti-programmed cell death protein 1 [PD-1] / programmed cell death ligand 1 [PD-L1]) combined with other components such as chemotherapy, a targeted small molecule drug, novel CPIs, or ADCs.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

Codon

MARCH 20, 2023

Marine biofilm engineered to produce current in response to small molecules. How cell-free processes could speed up vaccine development. 🏭 Industry SpyBiotech receives more than $4 million to develop vaccine platform. Point-of-care peptide hormone production enabled by cell-free protein synthesis. DeWinter MA.

Virus 52

Virus Engineering RNA DNA 52